ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Zeneca Says NSABP Was Tardy In Reporting Uterine Cancer Deaths

June 24, 1994

Florida Creates State Cancer Control Program

August 10, 1979

CT Finds Early Lung Tumors In Smokers, Former Smokers

March 31, 2006

Also M.D. Anderson awarded three new, one renewal SPORE grant.

October 31, 2003

Implants Don’t Cause Cancer, Long-Term Study Finds

May 26, 2006

NCAB Sets Bypass Budget Figures at $1.074 Billion

May 28, 1982